Soluble glycoprotein V for treating thrombotic diseases

A method for the treatment and/or prevention of a thrombotic disease in a subject, comprising administering to the subject an effective amount of a soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain,

• wherein the modified GPV comprises an amino acid sequence at least 75% identical to amino acids 1-503 of SEQ ID NO:3 or amino acids 1-502 of SEQ ID NO:7, and
• wherein the thrombotic disease is selected from the group consisting of thrombo-inflammatory conditions, venous thrombosis, arterial thrombosis, capillary thrombosis, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, cerebral venous sinus thrombosis, thrombus formation during or after contacting blood with an artificial surface, atherosclerosis, arthritis, coagulopathy, deep venous thrombosis (DVT), disseminated intravascular coagulopathy (DIC), a chronic or acute thromboembolism, pulmonary thromboembolism, Budd-Chiari syndrome, Paget-Schroetter diseases, stroke, and myocardial infarction.